Target Validation Information
Target ID T12475
Target Name Gonadotropin-releasing hormone receptor
Target Type
Successful
Drug Potency against Target Cetrorelix Drug Info IC50 = 1.21 nM [534464]
PGlu-His-Trp-Ser-His-D-Tyr-Leu-Arg-Pro-Gly-NH2 Drug Info IC50 = 8.1 nM [527975]
PGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 Drug Info IC50 = 4.1 nM [527975]
[D-Dap(CO-NH-OH)3]degarelix Drug Info IC50 = 3.46 nM [528235]
[D-Dab(CO-NH-OH)3]degarelix Drug Info IC50 = 2.68 nM [528235]
TAK-013 Drug Info IC50 = 0.6 nM [529431]
[D-Ncy(isopropyl)7]acyline Drug Info IC50 = 0.81 nM [528769]
[D-Ncy(SO,isopropyl)7]acyline Drug Info IC50 = 3 nM [528769]
[4Aph(CO-NH-OCH3)5]degarelix Drug Info IC50 = 0.6 nM [528235]
[D-Gln3,Ncy(SO2,isopropyl)7]acyline Drug Info IC50 = 3815 nM [528769]
[D-Ncy(methyl)4]acyline Drug Info IC50 = 25 nM [528769]
[Ncy(SO,isopropyl)7]acyline Drug Info IC50 = 3.2 nM [528769]
[D-Ncy(2-naphthyl)1]acyline Drug Info IC50 = 4.4 nM [528769]
[D-Gln3,Ncy(SO,isopropyl)7]acyline Drug Info IC50 = 13 nM [528769]
[D-Gln3,Ncy(isopropyl)7]acyline Drug Info IC50 = 6.2 nM [528769]
[Ncy(SO,methyl)4]acyline Drug Info IC50 = 4.6 nM [528769]
[4Aph(CO-NH-OCH3)5,D-4Aph(CO-NH-OCH3)6]degarelix Drug Info IC50 = 0.91 nM [528235]
ACYLINE Drug Info IC50 = 1.5 nM [528769]
[D-Ncy(methyl)10] acyline Drug Info IC50 = 1.7 nM [528769]
[4Aph(CO-NH-OH)5]degarelix Drug Info IC50 = 0.86 nM [528235]
[Ncy(2-naphthyl)1]acyline Drug Info IC50 = 2.2 nM [528769]
[D-Gln3,D-Ncy(SO2,isopropyl)7]acyline Drug Info IC50 = 2004 nM [528769]
[4Aph(CO-NH-(C2H4O)2-C2H5)5]degarelix Drug Info IC50 = 3.16 nM [528235]
[D-4Aph(CO-NH-(C2H4O)2-C2H5)6]degarelix Drug Info IC50 = 0.88 nM [528235]
[Ncy(isopropyl)7]acyline Drug Info IC50 = 2.5 nM [528769]
[4Aph(CO-(C2H4O)3-C2H4-NH-CO-NH-OCH3)5]degarelix Drug Info IC50 = 1.06 nM [528235]
[D-Dap(CO-NH-OCH3)3]degarelix Drug Info IC50 = 3.16 nM [528235]
[D-Gln3,D-Ncy(SO,isopropyl)7]acyline Drug Info IC50 = 85 nM [528769]
[Ncy(SO,methyl)10]acyline Drug Info IC50 = 0.87 nM [528769]
[D-Ncy(SO,methyl)4]acyline Drug Info IC50 = 6.9 nM [528769]
[D-Ncy(SO,methyl)10]acyline Drug Info IC50 = 0.83 nM [528769]
[Ncy(methyl)4]acyline Drug Info IC50 = 2.4 nM [528769]
[D-4Aph(CO-NH-OH)6]degarelix Drug Info IC50 = 0.8 nM [528235]
[D-4Aph(CO-NH-OCH3)6]degarelix Drug Info IC50 = 0.51 nM [528235]
[D-Dab(CO-NH-OCH3)3]degarelix Drug Info IC50 = 1.69 nM [528235]
[D-Gln3,D-Ncy(isopropyl)7]acyline Drug Info IC50 = 39 nM [528769]
AZALINE B Drug Info IC50 = 1.4 nM [528769]
[Ncy(methyl)10]acyline Drug Info IC50 = 1.7 nM [528769]
WAY-207024 Drug Info IC50 = 360 nM [530791]
LHRH Drug Info IC50 = 7 nM [534724]
NBI-42902 Drug Info Ki = 5.7 nM [536933]
References
Ref 534464Anal Biochem. 1997 Aug 15;251(1):17-23.Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay.
Ref 527975J Med Chem. 2006 Jan 26;49(2):637-47.Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
Ref 527975J Med Chem. 2006 Jan 26;49(2):637-47.Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 529431J Med Chem. 2008 Jun 26;51(12):3331-48.Non-peptide gonadotropin-releasing hormone receptor antagonists.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 528235J Med Chem. 2006 Jun 15;49(12):3536-43.Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 528769J Med Chem. 2007 May 3;50(9):2067-77. Epub 2007 Apr 3.Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Ref 530791Bioorg Med Chem Lett. 2010 Apr 15;20(8):2512-5. Epub 2010 Mar 3.Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor.
Ref 534724J Med Chem. 1998 Oct 22;41(22):4190-5.Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor.
Ref 536933Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008 Dec 11;51(23):7478-85.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.